Pak and Rac GTPases promote oncogenic KIT-induced neoplasms

Journal of Clinical Investigation

Volumn 123, Issue 10, 2013, Pages 4449-4463

  Martin, Holly ^a   Mali, Raghuveer Singh ^a   Ma, Peilin ^a   Chatterjee, Anindya ^a   Ramdas, Baskar ^a   Sims, Emily ^a   Munugalavadla, Veerendra ^b   Ghosh, Joydeep ^a   Mattingly, Ray R ^c   Visconte, Valeria ^d   Tiu, Ramon V ^d   Vlaar, Cornelis P ^e   Dharmawardhane, Suranganie ^f   Kapur, Reuben ^a,g  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e Universigy of Pittsburgh   (United States)

^f UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^g INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; FLUOROURACIL; P21 ACTIVATED KINASE; RAC1 PROTEIN; RAC2 PROTEIN; UNCLASSIFIED DRUG; VAV1 PROTEIN; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; N4-(9-ETHYL-9H-CARBAZOL-3-YL)-N2-(3-MORPHOLIN-4-YLPROPYL)-PYRIMIDINE-2,4-DIAMINE; PYRIMIDINE DERIVATIVE; RAC PROTEIN; STEM CELL FACTOR RECEPTOR; VAV PROTEIN; VAV1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; ENZYME INHIBITION; GENOTYPE; LIVER; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN; SYSTEMIC MASTOCYTOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; C3H MOUSE; C57BL MOUSE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; GENETICS; HUMAN; LEUKEMIA, MYELOID, ACUTE; MASTOCYTOSIS; METABOLISM; MISSENSE MUTATION; PHYSIOLOGY; TUMOR CELL LINE;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; CARBAZOLES; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MASTOCYTOSIS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MUTATION, MISSENSE; P21-ACTIVATED KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-VAV; PYRIMIDINES; RAC GTP-BINDING PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885056563     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67509     Document Type: Article

References (60)

1. Beghini A, et al. C-kit mutations in core binding factor leukemias. Blood. 2000;95(2):726-727.
2. Hirota S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-580.
3. Nagata H, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92(23):10560-10564.
4. Gerbaulet A, et al. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood. 2011;117(6):2012-2021.
5. Kitayama H, et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factorindependent growth and tumorigenicity of factordependent hematopoietic cell lines. Blood. 1995;85(3):790-798.
6. Piao X, Bernstein A. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood. 1996;87(8):3117-3123.
7. Tsujimura T, et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood. 1994;83(9):2619-2626.
8. Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res. 2011;35(9):1143-1152.
9. Pardanani A. Systemic mastocytosis in adults:2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86(4):362-371.
10. Munugalavadla V, Sims EC, Chan RJ, Lenz SD, Kapur R. Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT. Exp Hematol. 2008;36(3):301-308.
11. Ma P, Mali RS, Martin H, Ramdas B, Sims E, Kapur R. Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease. Leukemia. 2012;26(7):1499-1506.
12. Katzav S, Martin-Zanca D, Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J. 1989;8(8):2283-2290.
13. Katzav S. Vav1: a hematopoietic signal transduction molecule involved in human malignancies. Int J Biochem Cell Biol. 2009;41(6):1245-1248.
14. Fujikawa K, et al. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J Exp Med. 2003;198(10):1595- 1608.
15. Gakidis MA, et al. Vav GEFs are required for beta2 integrin-dependent functions of neutrophils. J Cell Biol. 2004;166(2):273-282.
16. Williams DA, Zheng Y, Cancelas JA. Rho GTPases and regulation of hematopoietic stem cell localization. Methods Enzymol. 2008;439:365-393.
17. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A. 2004;101(20):7618-7623.
18. Montalvo-Ortiz BL, et al. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase. J Biol Chem. 2012;287(16):13228-13238.
19. Arias-Romero LE, Chernoff J. A tale of two Paks. Biol Cell. 2008;100(2):97-108.
20. Eswaran J, Soundararajan M, Knapp S. Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev. 2009;28(1-2):209-217.
21. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem. 1998;273(43):28238-28246.
22. Delorme V, et al. Cofilin activity downstream of Pak1 regulates cell protrusion efficiency by organizing lamellipodium and lamella actin networks. Dev Cell. 2007;13(5):646-662.
23. Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol. 1997;7(3):202-210.
24. Balasenthil S, et al. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem. 2004;279(2):1422-1428.
25. Ito M, et al. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. J Urol. 2007;178(3 pt 1):1073-1079.
26. Schraml P, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13. 5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol. 2003;163(3):985-992.
27. Mali RS, et al. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 2011;20(3):357-369.
28. Oberley MJ, Wang DS, Yang DT. Vav1 in hematologic neoplasms, a mini review. Am J Blood Res. 2012;2(1):1-8.
29. Gu Y, et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science. 2003;302(5644):445-449.
30. Chan PM, Manser E. PAKs in human disease. Prog Mol Biol Transl Sci. 2012;106:171-187.
31. Ong CC, et al. p21-activated kinase 1: PAK'ed with potential. Oncotarget. 2011;2(6):491-496.
32. Ong CC, et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2011;108(17):7177-7182.
33. Deacon SW, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol. 2008;15(4):322-331.
34. Schnelzer A, et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000;19(26):3013-3020.
35. Chan AY, et al. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene. 2005;24(53):7821-7829.
36. Burbelo P, Wellstein A, Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat. 2004;84(1):43-48.
37. Singer S, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20(18):3898-3905.
38. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1(12):1115-1124.
39. Ma Y, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741-1744.
40. Rossman KL, der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005;6(2):167-180.
41. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 2002;16(13):1587-1609.
42. Palmby TR, Abe K, Karnoub AE, der CJ. Vav transformation requires activation of multiple GTPases and regulation of gene expression. Mol Cancer Res. 2004;2(12):702-711.
43. Miller SL, DeMaria JE, Freier DO, Riegel AM, Clevenger CV. Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol Endocrinol. 2005;19(4):939-949.
44. Minard ME, Kim LS, Price JE, Gallick GE. The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat. 2004;84(1):21-32.
45. Liu BP, Burridge K. Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not beta1 integrins. Mol Cell Biol. 2000;20(19):7160-7169.
46. Chrencik JE, et al. Structural basis of guanine nucleotide exchange mediated by the T-cell essential Vav1. J Mol Biol. 2008;380(5):828-843.
47. Abe K, et al. Vav2 is an activator of Cdc42, Rac1, and RhoA. J Biol Chem. 2000;275(14):10141-10149.
48. Thomas EK, et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell. 2007;12(5):467-478.
49. Binker MG, Binker-Cosen AA, Gaisano HY, Cosen-Binker LI. Inhibition of Rac1 decreases the severity of pancreatitis and pancreatitis-associated lung injury in mice. Exp Physiol. 2008;93(10):1091-1103.
50. Furitsu T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligandindependent activation of c-kit product. J Clin Invest. 1993;92(4):1736-1744.
51. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 1991;77(9):2031-2036.
52. Roberts AW, et al. Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. Immunity. 1999;10(2):183-196.
53. Turner M, et al. A requirement for the Rhofamily GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity. 1997;7(4):451-460.
54. Florian MC, et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell. 2012;10(5):520-530.
55. Peterson JR, Lebensohn AM, Pelish HE, Kirschner MW. Biochemical suppression of small-molecule inhibitors: a strategy to identify inhibitor targets and signaling pathway components. Chem Biol. 2006;13(4):443-452.
56. Tan BL, et al. Genetic evidence for convergence of c-Kit- and alpha4 integrin-mediated signals on class IA PI-3kinase and the Rac pathway in regulating integrin-directed migration in mast cells. Blood. 2003;101(12):4725-4732.
57. Traina F, et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One. 2012;7(8):e43090.
58. Tang Y, Zhou H, Chen A, Pittman RN, Field J. The Akt proto-oncogene links Ras to Pak and cell survival signals. J Biol Chem. 2000;275(13):9106-9109.
59. Williams DA, et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood. 2000;96(5):1646-1654.
60. Li Q, Mullins SR, Sloane BF, Mattingly RR. p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia. 2008;10(4):314-329.